Moolec Science (MLEC)
NASDAQ:MLEC
Want to see MLEC full AI Analyst Report?
MLEC Stock Chart & Stats
$8.93
-$0.04(-4.25%)
At close: 4:00 PM EST
$8.93
-$0.04(-4.25%)
Day’s Range― - ―
52-Week Range$3.08 - $120.00
Previous CloseN/A
Volume11.69K
Average Volume (3M)209.37K
Market Cap
$4.96M
Enterprise Value$251.58M
Total Cash (Recent Filing)$1.93M
Total Debt (Recent Filing)$22.09M
Price to Earnings (P/E)―
Beta-0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding726,118
10 Day Avg. Volume506,476
30 Day Avg. Volume209,369
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.12
P/FCF Ratio-1.35
Enterprise Value/Market Cap50.73
Enterprise Value/Revenue32.12
Enterprise Value/Gross Profit-393.40
Enterprise Value/Ebitda-48.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Molecular Farming Business ModelMoolec’s core model engineers crops to yield targeted food ingredients, a durable structural play in sustainable protein/oil supply. Agricultural-scale production can deliver cost and capacity advantages versus fermentation, supporting long-term customer partnerships and repeated ingredient sales as adoption grows.
Sharp Revenue Ramp And Margin ImprovementA large revenue increase alongside a material gross margin improvement signals early commercialization traction and better unit economics. If sustained, higher gross margins help absorb fixed R&D and processing costs, improving path to operating leverage as volumes and customer contracts scale over months to years.
New Controlling Shareholder SupportAIGC’s 65% stake centralizes ownership and can supply strategic capital and governance support, reducing short-term refinancing pressure. Active majority ownership can speed commercialization decisions, coordinate partnerships, and help secure operational funding needed to scale production and market access.
Bears Say
Materially Weakened Balance SheetNegative equity and elevated borrowings materially reduce financial flexibility and increase solvency risk. High leverage constrains the company’s ability to fund capital-intensive scale-up or absorb setbacks without dilutive or costly refinancing, making long-term planning and partner confidence more difficult.
Ongoing Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow imply continued reliance on external funding to support operations and scale. Persistent cash burn reduces runway, increases the likelihood of dilutive financing or onerous debt terms, and can divert management focus from commercial execution to capital raises.
Nasdaq Monitoring And Continued Compliance RiskOne-year Nasdaq monitoring signals fragile listing metrics and elevated regulatory scrutiny. Ongoing compliance demands increase disclosure and governance burdens, and failure to sustain metrics could threaten listing status, raise cost of capital, and impair long-term investor and partner confidence.
Moolec Science News
MLEC FAQ
What was Moolec Science’s price range in the past 12 months?
Moolec Science lowest stock price was $3.08 and its highest was $120.00 in the past 12 months.
What is Moolec Science’s market cap?
Moolec Science’s market cap is $4.96M.
When is Moolec Science’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Moolec Science’s earnings last quarter?
Currently, no data Available
Is Moolec Science overvalued?
According to Wall Street analysts Moolec Science’s price is currently Overvalued.
Does Moolec Science pay dividends?
Moolec Science does not currently pay dividends.
What is Moolec Science’s EPS estimate?
Moolec Science’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moolec Science have?
Moolec Science has 726,118 shares outstanding.
What happened to Moolec Science’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Moolec Science?
Currently, no hedge funds are holding shares in MLEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moolec Science
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.
Technical Analysis
AIM ImmunoTech
―
Ensysce Biosciences
―
Cyclerion Therapeutics
―
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---